STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #751 by analyst upside · 2026-09-05
COLL
Collegium Pharmaceutical, Inc.
Healthcare · Market Cap $729M · P/E 18.5x
ANALYST PRICE TARGET
+110.8%
implied upside to consensus target
Current Price $23.53
Consensus Target $49.6
Bull Target $60.0
Bear Target $43.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
2
Hold
1
Sell
0
52-Week Low $23.37
52-Week High $50.79
YTD Return -48.3%
FUNDAMENTALS
Market Cap $729M
P/E Ratio (TTM) 18.5x
Forward P/E 3.5x
EPS (TTM) $1.27
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $808M
Profit Margin 5.9%
52-WEEK RANGE
52-Week Low $23.37
52-Week High $50.79
Current Price $23.53
Bear Target $43.0
Bull Target $60.0
● Now $23.53 ● Target $49.6
TRADING DATA
Avg Volume 596K
YTD Return -48.3%
Analyst Count 5
Consensus Buy
Upside to Target +110.8%
Last Updated 2026-09-05

ANALYST SUMMARY

Collegium Pharmaceutical, Inc. (COLL) is currently trading at $23.53 with a Wall Street consensus price target of $49.6, implying potential upside of 110.8% over the next 12 months. 5 analysts currently cover COLL, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $60.0, while the most cautious has a target of $43.0.

COLL operates in the Healthcare sector with a market capitalisation of $729M. The stock is down 48.3% year-to-date and is currently trading near the lower end of its 52-week range of $23.37 – $50.79.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for COLL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Overweight → Overweight 2026-08-19 Building track record
Piper Sandler reit
Neutral → Neutral 2026-08-07 14% win rate (7 calls)
Needham - Reiterated
Buy → Buy 2026-08-06 20% win rate (5 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-20 31% win rate (48 calls)
Needham reit
Buy → Buy 2026-03-19 20% win rate (5 calls)
Needham - Reiterated
Buy → Buy 2026-02-26 20% win rate (5 calls)
Barclays - Reiterated
Overweight → Overweight 2026-01-09 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-01-09 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
52
out of 100
Coverage depth
14/30
Consensus clarity
16/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →